Tubulis, a Munich‑based antibody‑drug conjugate (ADC) developer, closed a roughly $361 million financing to accelerate clinical testing of its lead ADCs, including TUB‑040 in ovarian and non‑small‑cell lung cancers. The Series C will fund expanded trials in additional tumor types and earlier lines of therapy and support the company’s pipeline optimization and manufacturing scale‑up. The capital injection follows the company’s decision to present initial clinical data at a major oncology conference and positions Tubulis to compete in an increasingly crowded ADC space. Management emphasized the financing allows testing ADCs in broader patient populations and advancing next‑generation linker/toxin chemistries. For investors and competitors, the round highlights sustained appetite for ADC platforms with differentiated payload delivery and tumor targeting. Tubulis’ near‑term milestones will include expanded safety cohorts, combination studies and regulatory interactions tied to emerging clinical readouts.